INTC — Intel Corp.

The tape is momentum-bullish as of 2026-09-13: +124.91% over six months, +7.45% in the latest week, RSI(14) at 57.53, and price 36.28% above the 200-day SMA. The catalysts behind the run are concrete rather than purely narrative: reported ~10% PC CPU price increases from October, a Northland upgrade to Outperform with a $120 target citing server CPU supply tightness, a SpaceX/Tesla alignment on the ~$55B Texas 'Terafab' complex, Altera IPO preparation (up to $2B), and DCAI revenue growth of 59%. What that enthusiasm does not reflect is institutional conviction: the analyst breakdown in this dataset shows 0 strong buy, 32 buy, 46 hold and 7 sell, with a consensus rating of Hold and a $110.03 price target — only about 7% above the 2026-09-13 price of $102.94. Retail and momentum money is carrying this stock, not sell-side sponsorship.

This is an inflection, not a blip. Revenue bottomed at $12.67B in Q1 2025 and has since accelerated on a YoY basis: +2.8% (Q3 2025, $13.65B), -4.1% (Q4 2025, $13.67B), +7.2% (Q1 2026, $13.58B), +25.4% (Q2 2026, $16.13B) — two consecutive quarters of accelerating growth and a step-change in the June quarter. Margins confirm it: gross margin went from 27.5% in Q2 2025 to 41.5% in Q2 2026 ($6.69B), and operating income flipped from -$3.18B to +$1.98B (a 12.3% operating margin versus -24.7% a year earlier), while R&D was trimmed from $3.68B to $3.37B. Free cash flow is the cleanest evidence: the series shows twelve mostly-negative quarters (Q1 2024 alone burned -$7.19B), then +$121M, +$800M, -$2.54B, and finally +$4.45B in Q2 2026 as capex fell to $2.56B from $3.64B the prior quarter and $5-6.7B per quarter during 2024 — TTM FCF is now +$2.83B, the first positive reading in the window. Two serious caveats. First, the GAAP bottom line remains a mess: Q2 2026 delivered a -$11.03B net loss on +$1.98B of operating income, an ~$13B non-operating gap, and stockholders' equity collapsed from $111.4B to $87.5B in a single quarter even as long-term debt rose to $48.5B. Second, base effects flatter the comparison — Q2 2025 carried a -$3.18B operating loss and Q3 2024 carried a -$16.6B net loss with gross profit collapsing to $2.0B. Normalized, Q2 2026's $16.13B in revenue is still only modestly above the $15.41B Intel printed back in Q4 2023.

Expensive. As of 2026-09-13 at $102.94, TTM EPS of -$2.21 makes the trailing P/E ratio meaningless (-48.8x), and the PEG ratio of 0.004 is a degenerate output of negative earnings rather than a signal. The usable anchor is forward: $102.94 divided by next-FY EPS of $1.501 is roughly 68.6x. Price/sales is 9.10x against a 5-year average of 2.64x; price/book is 6.00x on equity that just shrank 21% in one quarter; EV/EBITDA is 153x; the deterministic ratio screener scored only 66.9, and its EV/EBITDA and P/B inputs were among the weakest legs. Intel's 3-year average P/E of 49.89x is the one number that makes this look less extreme, but that average is itself distorted by years of near-zero earnings — it is not a truthful 'normal' multiple. Even on generous recovery math (FY2027 EPS of ~$2.10), the stock trades near 49x, roughly double a typical mature semiconductor multiple. There is no valuation cushion here.

The price is discounting earnings that have not shown up yet. At $102.94 on next-FY consensus EPS of $1.501 you are paying 68.6x for a business with a 0.1% TTM operating margin and a -19.8% TTM net margin — the market is underwriting FY2027 through FY2029, not the next four quarters. For today's price to be justified on a normal 30-35x semiconductor multiple, EPS has to reach roughly $3.00, double the current run-rate; a full return to 2021-level profitability (~20% net margin on ~$80B of revenue, ~$16B of net income) is what is effectively embedded in the $519B market cap. That is achievable but requires the ~10% CPU pricing action to stick, DCAI's 59% growth to persist, and foundry losses to narrow from the -$2.1B quarterly level. Read the prints accordingly: the guided ~$0.38 non-GAAP EPS for Q3 2026 will barely matter; gross margin trajectory, foundry loss narrowing, and any change to capital intensity are the real variables. The flip side of the playbook is that on trailing GAAP numbers Intel looks broken and loss-making, which is precisely why the deterministic score's cash-flow-based legs read better than its earnings-based ones.

As of 2026-09-13, RSI(14) stood at 57.53 — neutral, neither overbought nor oversold, with plenty of room in either direction. Price was 8.81% above the 20-day SMA, 4.66% above the 50-day SMA, and 36.28% above the 200-day SMA (implying a 200-day level near $75.50). The previous close was $100.32; the stock was +7.45% on the week, +1.97% on the month, -17.36% over three months, and +124.91% over six months, and sits 27.7% below its 52-week high of $142.35. That combination — a violent six-month advance, a double-digit three-month drawdown, and price reclaiming the shorter moving averages while remaining extremely extended versus the long-term trend — reads as a post-parabolic consolidation attempting to resume. The entry-timing implication is unambiguous: buying here means paying 36% above the 200-day after a 125% run, into a print that is already well anticipated. A retest of the 50-day or a multi-week base above $95 would offer materially better risk/reward than chasing the current $103 level.

• AI/compute supercycle: hyperscaler demand for server CPUs and accelerators is tight enough that Intel's DCAI revenue grew 59%; the 'starving for compute' backdrop is currently doing more for the narrative than any Intel-specific product win.
• Rate sensitivity: INTC's beta is 2.231, and a 68.6x forward earnings multiple is a long-duration asset — any sustained rise in real yields or risk-off rotation compresses this valuation far faster than it would a 20x-earnings peer.
• US industrial policy and export controls: semiconductor subsidies and domestic-fab incentives support the foundry story, while China export restrictions cut both ways, framing the opportunity and the revenue risk simultaneously.
• Foundry capital intensity and cost of capital: the ~$55B Terafab Phase 1 with SpaceX/Tesla, $48.5B of long-term debt, and a freshly completed $20B equity offering make Intel hostage to capital markets staying open and receptive.
• Three-front competitive structure: NVIDIA pushing into PC CPUs (N1X with Microsoft), AMD in servers, and TSMC/Samsung in foundry means Intel has to defend its cash-generating core while funding a costly manufacturing catch-up.

• Q3 2026 earnings, expected late October 2026 — management has guided to $15.8-16.8B of revenue and ~$0.38 non-GAAP EPS. The read-throughs that matter are whether the rumored ~10% PC CPU price increase landed and whether gross margin extends beyond Q2's 41.5%.
• Altera IPO progress (reportedly raising up to $2B) — a successful carve-out would crystallize value in a non-core asset and give investors a cleaner sum-of-the-parts read.
• Intel 18A/14A external customer commitments and yield milestones — the High-NA EUV line has processed over one million wafers jointly with ASML; any named external customer would be the single biggest swing factor for narrowing the -$2.1B quarterly foundry loss.
• Continued DCAI momentum above 50% YoY growth, which would reinforce the AI-infrastructure re-rating — or, conversely, any sign that the server CPU supply squeeze is easing and pricing power is fading.

• Valuation with no margin of safety: 68.6x forward EPS, 9.10x TTM sales versus a 2.64x 5-year average, 6.00x book, and 153x EV/EBITDA. One soft guide can compress the multiple and the estimate at the same time, and a 2.231 beta means the drawdown would be amplified.
• Unresolved earnings quality: Q2 2026 produced a -$11.03B GAAP net loss alongside +$1.98B of operating income, with stockholders' equity falling ~$23.9B in a single quarter. Whatever drove that gap is not explained in the data provided and is a genuine unknown rather than a mere accounting curiosity.
• Foundry economics plus dilution: a -$2.1B quarterly foundry operating loss, $48.5B of long-term debt, and a $20B common stock offering completed in August 2026 (~3.8% dilution at current prices) that post-dates the 2026-06-27 balance sheet — the trailing fundamentals cannot see it.
• Dividend coverage: a 2.633% yield on a $519.2B market cap implies roughly $13.7B of annual cash dividends against TTM free cash flow of just $2.83B. The payout is not covered by organic cash generation.
• Core franchise erosion: NVIDIA's N1X chip with Microsoft directly targets the PC CPU socket that funds the entire turnaround, and AMD remains aggressive in servers.
• Crowded, thinly-sponsored setup: sell-side consensus is Hold with a $110.03 target, only ~7% above the 2026-09-13 price, so if momentum flows reverse there is little fundamental bid underneath.

The operating turn is real and the numbers prove it: revenue +25.4% YoY, gross margin back to 41.5%, operating income of +$1.98B versus -$3.18B a year ago, and +$4.45B of free cash flow in a quarter that also saw capex step down to $2.56B. The balance sheet is still serviceable (debt/equity 0.577, current ratio 1.604), and the foundry/AI optionality is genuine. The problem is entirely price. At $102.94 as of 2026-09-13 you are paying ~69x forward EPS of $1.50 and 9.1x sales for a business that still prints GAAP losses, still loses ~$2.1B a quarter in foundry, and just diluted holders by ~3.8% to raise $20B. My own valuation work lands near $82, so the honest read is a genuinely improving company trading at a demanding price — the fundamentals and momentum lean positive, but this is a stock to accumulate on a real pullback rather than chase after a 125% six-month run.

Two-stage forward multiple blend, computed independently from the FMP data as of 2026-09-13. (1) Forward P/E: I estimate FY2027 EPS of $2.10 (growing off the FY-next consensus of $1.501 plus ~40% from PC CPU price hikes, server CPU mix, and foundry loss narrowing) and apply 38x — a premium to the typical 25-30x mature-semiconductor multiple but well below Intel's distorted 3-year average of 49.89x and its current 68.6x forward multiple — giving $79.80. (2) Cross-check on forward P/S: $68B of FY2027E revenue at 6.4x sales (still 2.4x the 5-year average of 2.64x) yields a $435B market cap, or $83.02 on 5.24B diluted shares after the $20B August 2026 raise. Averaging the two methods gives ~$81.40, which I round to $82.00 — roughly 20% below the 2026-09-13 price of $102.94, implying the market has already priced a full return to 2021-level profitability without discounting execution risk.